Ralliant (NYSE:RAL) Rating Lowered to “Buy” at Wall Street Zen

Ralliant (NYSE:RAL) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Sunday, Wall Street Zen reports.

Other equities research analysts have also issued research reports about the stock. Barclays lifted their target price on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Evercore began coverage on shares of Ralliant in a report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price objective for the company. Royal Bank Of Canada lifted their price objective on Ralliant from $71.00 to $73.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. Citigroup upped their target price on Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Oppenheimer raised their target price on Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ralliant presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.70.

Ralliant Stock Performance

Shares of RAL stock opened at $61.55 on Friday. The company has a market capitalization of $6.81 billion, a P/E ratio of -5.67, a PEG ratio of 2.29 and a beta of 1.61. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. The stock has a 50 day moving average price of $68.28 and a two-hundred day moving average price of $56.66.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. The firm had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Analysts expect that Ralliant will post 2.87 earnings per share for the current year.

Insiders Place Their Bets

In other Ralliant news, CEO Tamara S. Newcombe sold 12,936 shares of Ralliant stock in a transaction on Friday, August 14th. The stock was sold at an average price of $71.79, for a total transaction of $928,675.44. Following the completion of the transaction, the chief executive officer owned 251,967 shares in the company, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen M. Bick sold 6,062 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the sale, the senior vice president directly owned 31,668 shares in the company, valued at $2,280,096. This trade represents a 16.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by insiders.

Institutional Trading of Ralliant

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Ralliant during the 2nd quarter valued at about $1,039,481,000. Irenic Capital Management LP lifted its stake in shares of Ralliant by 424.1% in the 1st quarter. Irenic Capital Management LP now owns 1,740,218 shares of the company’s stock worth $72,376,000 after purchasing an additional 1,408,176 shares during the period. Rokos Capital Management LLP bought a new position in shares of Ralliant in the 1st quarter worth approximately $42,022,000. Flossbach Von Storch SE purchased a new position in shares of Ralliant in the second quarter worth approximately $222,460,000. Finally, California State Teachers Retirement System boosted its holdings in shares of Ralliant by 23.1% in the first quarter. California State Teachers Retirement System now owns 130,822 shares of the company’s stock worth $5,441,000 after buying an additional 24,591 shares during the last quarter.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.